Results 51 to 60 of about 272,115 (210)

Aptamer-based therapeutics and their potential in radiopharmaceutical design [PDF]

, 2007
Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications.
Ferreira, Catia S. M., Missailidis, Sotiris   +1 more
core   +3 more sources

Anti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammation. [PDF]

, 2014
PURPOSE: To evaluate whether anti-vascular endothelial growth factor (VEGF) neutralizing antibodies injected in the vitreous of rat eyes influence retinal microglia and macrophage activation.
Behar-Cohen, F., Bousquet, E., Couturier, A., de Kozak, Y., Jonet, L., Klein, C., Naud, M.C., Tadayoni, R., Zhao, M.   +8 more
core   +3 more sources

Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma [PDF]

, 2016
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening ...
Andrés Guerrero, Vanessa, García Feijoo, Julián, Herrero Vanrell, Rocío, Konstas, Anastasios Georgios P., Martínez de la Casa, Jose Maria, Morales Fernández, Laura, Pablo Júlvez, Luis, Perucho González, Lucía, Polo Llorens, Vicente, Sáenz Francés, Federico   +9 more
core   +4 more sources

Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry

Scientific Reports
To compare baseline characteristics, initial response and 12-month efficacy and safety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexamethasone implants (DEX) or anti-vascular endothelial growth factor ...
Gonzaga Garay-Aramburu, Adrian Hunt, Carolina Arruabarrena, Hemal Mehta, Alessandro Invernizzi, Pierre-Henry Gabrielle, Tremeur Guillaumie, Benjamin Wolff, Mark C. Gillies, Javier Zarranz-Ventura   +9 more
doaj   +1 more source

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Scientific Reports, 2023
To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included
Sheng-Chu Chi, Yi-No Kang, Yi-Ming Huang
doaj   +1 more source

A study of the relationship between cytokine levels and the response to anti-VEGF therapy in polypoid choroidal vasculopathy with different choroidal thicknesses

Frontiers in Endocrinology
PurposePolypoidal choroidal vasculopathy (PCV) is an irreversible retinal choroidal disease. Individuals with PCV exhibit diverse baseline characteristics, including systemic characteristics, ocular traits, metabolic factor levels, and different ...
Su Dong, Pan Fan, Haotian Yu, Bo Jiang, Dawei Sun   +4 more
doaj   +1 more source

Glaucoma Drainage Device Erosions in Patients Receiving Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy

Clinical Ophthalmology, 2022
Yasmin Florence Khodeja Islam, Elizabeth A Vanner, Arindel SR Maharaj, Stephen G Schwartz, Krishna Kishor Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Krishna ...
Islam YFK, Vanner EA, Maharaj ASR, Schwartz SG, Kishor K   +4 more
doaj  

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]

, 2018
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini, Bodis-Wollner, Brilliant, Brown, Chung, Cutroneo, de Jong, Ding, Drake, Enders, Falk, Gibson, Kemp, Krum, Miners, Naranjo, Nowacka, Nowacka, Piltonen, Pitzer, Poewe, Postuma, Pratt, Quittet, Rosenfeld, Shamloo, Sheikh, Silverman, Slotnick, Stewart, Storkebaum, Tian, Trost, Ueta, Whitton, Wu, Yasuda, Yasuhara, Yasuhara, Yasuhara, Yla-Herttuala, Yue, Zachary, Zehetner   +43 more
core   +2 more sources

Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models

Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors show limited efficacy against immune-desert tumors, including ovarian cancer. We investigated triple therapy combining anti-programmed cell death-ligand 1 (PD-L1) antibody, anti-vascular endothelial growth factor ...
Akihiko Ueda, Ryusuke Murakami, Kentaro Ishida, Kohei Hamada, Jumpei Ogura, Shunsuke Kawahara, Yuka Mise, Yuko Hosoe, Masamichi Sugimoto, Daiko Wakita, Taito Miyamoto, Rin Mizuno, Mana Taki, Koji Yamanoi, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai   +16 more
doaj   +1 more source

Human Platelets Take up Anti-VEGF Agents

Journal of Ophthalmology, 2021
Purpose. Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application.
B. Sobolewska, B. Fehrenbacher, P. Münzer, H. Kalbacher, S. Geue, Konstantinos Stellos, M. Schaller, F. Ziemssen   +7 more
doaj   +1 more source